Hi @Koukku1
Thanks for your contribution. However, I would like to kindly remind you of the section in the investment forum rules which states that:
Recently, there have been several posts in the thread that appear to be largely or entirely AI-generated. Such long AI responses can easily be quite heavy to read, and the added value of a few lines of your own quality analysis can be much greater. Everyone can spar with AI about the topic themselves if they wish. It is also, of course, proper etiquette to mention which part of the post is AI-generated.
Shall we continue the discussion among humans, and use AI for screening, summarizing, and proofreading where it excels?
…
Then to the contribution itself: Your post should probably be interpreted to mean that Roche is hardly the mysterious Big Pharma partner, at least based on this, but AstraZeneca could be a possible option. Personally, I don’t grasp what Roche’s OCT images have to do with Optomed, nor why this Roche part is relevant to an Optomed investor in the first place.